SCHEMBL10054832

SCHEMBL10054832

Cc1ccc(NC(=O)c2ccc(Cl)cc2Cl)cc1NC(=O)/C=C/c1cncnc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.54
▸ RAB9A P51151 5/20 0.54
▸ TP53 P04637 1/20 0.47
▸ JAK2 O60674 1/20 0.46
▸ JAK1 P23458 1/20 0.46
▸ TYK2 P29597 1/20 0.46
▸ GPR27 Q9NS67 2/20 0.46
▸ CYP11B2 P19099 1/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ EGFR P00533 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ NR1H4 Q96RI1 1/20 0.43
▸ AVPR2 P30518 1/20 0.43
▸ NAMPT P43490 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ PYGL P06737 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2679953 1.00 NPC1 (0.54) NPC1RAB9ATP53JAK2JAK1
SCHEMBL2679679 0.90 NAMPT (0.56) NPC1RAB9ACYP11B2MEN1KMT2A
SCHEMBL10054801 0.90 NAMPT (0.56) NPC1RAB9ACYP11B2MEN1KMT2A
SCHEMBL10054898 0.84 NPC1 (0.51) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL2679168 0.82 SNCA (0.48) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL10054831 0.82 SNCA (0.48) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL2679308 0.82 MAPT (0.49) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL10078767 0.81 MAPT (0.49) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL2679844 0.81 MAPT (0.49) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL2678790 0.81 LCK (0.48) NPC1RAB9ATP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 — — US disclosed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 — — US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 — — US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR NPC1 4708/4885RAB9A 4310/4885TP53 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback